Article Text
Statistics from Altmetric.com
Case
A 68-year-old woman presented with 3 weeks of progressive left-sided weakness. She had a history of Sjögren’s syndrome, complicated by mononeuritis multiplex and arteritic anterior ischaemic optic neuropathy, and had taken azathioprine for 14 months. On examination, she was disorientated, inattentive, with a left hemiparesis and extensor left plantar response. MR scan of brain showed asymmetrical bilateral frontoparietal leukoencephalopathy, involving U-shaped fibres and deep white matter, with foci of diffusion restriction in the right frontoparietal and left parietal lobes, and a thin, linear, gyriform susceptibility weighted imaging (SWI)-hypointense rim in the periphery of the lesion (figure 1). Cerebrospinal fluid (CSF) examination showed 2 white cells/µL (≤5), glucose 5.6 mmol/L (2.5–4.4) and protein 0.44 g/L (0.15–0.45); Gram stain was negative. Quantitative DNA polymerase chain reaction (PCR) in CSF for JC (John Cunningham) polyomavirus was positive, supporting the diagnosis of progressive multifocal leukoencephalopathy (PML), an infective and life-threatening demyelinating disease of …
Footnotes
Twitter @neuro_Vinicius, @filipepsarmento, @fraiman
Contributors VLB conceived of the pathway and project, wrote the first draft and submmited. PF and FPS executed and wrote the first draft. DBB and HBF provided expert advice and reviewed the manuscript. EMLdO supervised the project and reviewed the manuscript and gave expert opinions. All authors approved the final version of this manuscript.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests PF is an editorial board member of the neurology resident and fellow section. VLB, FPS, DBB, HBF and EMLdO declare that there are no conflicts of interest relevant to this work.
Provenance and peer review Not commissioned; externally peer reviewed by Aaron Berkowitz, San Francisco, USA.
Read the full text or download the PDF:
Other content recommended for you
- Pharmacovigilance during treatment of multiple sclerosis: early recognition of CNS complications
- Changes to anti-JCV antibody levels in a Swedish national MS cohort
- Inflammatory natalizumab-associated PML: baseline characteristics, lesion evolution and relation with PML-IRIS
- Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies
- Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients
- MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance
- MRI pattern in asymptomatic natalizumab-associated PML
- Progressive multifocal leukoencephalopathy in individuals with minimal or occult immunosuppression
- Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group
- Progressive multifocal leukoencephalopathy as the first presentation of sarcoidosis